Resistance to Human Immunodeficiency Virus Type 1 Protease Inhibitors

The emergence of drug resistance complicating anti-human immunodeficiency virus type 1 (HIV-1) therapy remains a significant limitation in the clinical utility of inhibitors directed against specific HIV enzymatic targets. Viral resistance is a direct consequence of genetic diversity. The inherent

[1]  R Rode,et al.  Ritonavir and saquinavir combination therapy for the treatment of HIV infection. , 1999, AIDS.

[2]  Brendan Larder,et al.  A Rapid Method for Simultaneous Detection of Phenotypic Resistance to Inhibitors of Protease and Reverse Transcriptase in Recombinant Human Immunodeficiency Virus Type 1 Isolates from Patients Treated with Antiretroviral Drugs , 1998, Antimicrobial Agents and Chemotherapy.

[3]  N. Chirgadze,et al.  Viracept (nelfinavir mesylate, AG1343): a potent, orally bioavailable inhibitor of HIV-1 protease. , 1997, Journal of medicinal chemistry.

[4]  P. Pagano,et al.  In vitro combination of PNU-140690, a human immunodeficiency virus type 1 protease inhibitor, with ritonavir against ritonavir-sensitive and -resistant clinical isolates , 1997, Antimicrobial agents and chemotherapy.

[5]  A. Patick,et al.  Activities of the human immunodeficiency virus type 1 (HIV-1) protease inhibitor nelfinavir mesylate in combination with reverse transcriptase and protease inhibitors against acute HIV-1 infection in vitro , 1997, Antimicrobial agents and chemotherapy.

[6]  Remco,et al.  pol gene diversity of five human immunodeficiency virus type 1 subtypes: evidence for naturally occurring mutations that contribute to drug resistance, limited recombination patterns, and common ancestry for subtypes B and D , 1997, Journal of virology.

[7]  J. Falloon,et al.  Drug resistance during indinavir therapy is caused by mutations in the protease gene and in its Gag substrate cleavage sites , 1997, Journal of virology.

[8]  J. Weber,et al.  Emergence of resistant variants of HIV in vivo during monotherapy with the proteinase inhibitor saquinavir. , 1997, The Journal of antimicrobial chemotherapy.

[9]  D. Ho,et al.  Antiviral activity of the dihydropyrone PNU-140690, a new nonpeptidic human immunodeficiency virus protease inhibitor , 1997, Antimicrobial agents and chemotherapy.

[10]  E D Blair,et al.  Human Immunodeficiency Virus , 1996, The Journal of Biological Chemistry.

[11]  H. B. Schock,et al.  Mutational Anatomy of an HIV-1 Protease Variant Conferring Cross-resistance to Protease Inhibitors in Clinical Trials , 1996, The Journal of Biological Chemistry.

[12]  J. Mellors,et al.  Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor , 1996, Journal of virology.

[13]  J. Goudsmit,et al.  Human immunodeficiency virus type 1 subtypes defined by env show high frequency of recombinant gag genes. The UNAIDS Network for HIV Isolation and Characterization , 1996, Journal of virology.

[14]  E. De Clercq,et al.  Resistance-related mutations in the HIV-1 protease gene of patients treated for 1 year with the protease inhibitor ritonavir (ABT-538) , 1996, AIDS.

[15]  David J. Livingston,et al.  Kinetic Characterization of Human Immunodeficiency Virus Type-1 Protease-resistant Variants* , 1996, The Journal of Biological Chemistry.

[16]  D. Ho,et al.  Ordered accumulation of mutations in HIV protease confers resistance to ritonavir , 1996, Nature Medicine.

[17]  D. Lamarre,et al.  Second locus involved in human immunodeficiency virus type 1 resistance to protease inhibitors , 1996, Journal of virology.

[18]  M. Ott,et al.  In vivo resistance to a human immunodeficiency virus type 1 proteinase inhibitor: mutations, kinetics, and frequencies. , 1996, The Journal of infectious diseases.

[19]  T. Merigan,et al.  Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. AIDS Clinical Trials Group. , 1996, The New England journal of medicine.

[20]  D. Ho,et al.  Antiviral and resistance studies of AG1343, an orally bioavailable inhibitor of human immunodeficiency virus protease , 1996, Antimicrobial agents and chemotherapy.

[21]  M. Kosa,et al.  Preclinical pharmacokinetics and distribution to tissue of AG1343, an inhibitor of human immunodeficiency virus type 1 protease , 1996, Antimicrobial agents and chemotherapy.

[22]  D. Ho,et al.  A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection. , 1995, The New England journal of medicine.

[23]  H. B. Schock,et al.  Three-dimensional Structure of a Mutant HIV-1 Protease Displaying Cross-resistance to All Protease Inhibitors in Clinical Trials (*) , 1995, The Journal of Biological Chemistry.

[24]  R. Myers,et al.  In vitro selection and characterization of human immunodeficiency virus type 1 (HIV-1) isolates with reduced sensitivity to hydroxyethylamino sulfonamide inhibitors of HIV-1 aspartyl protease , 1995, Journal of virology.

[25]  E D Blair,et al.  Cross-resistance analysis of human immunodeficiency virus type 1 variants individually selected for resistance to five different protease inhibitors , 1995, Antimicrobial agents and chemotherapy.

[26]  L. M. Mansky,et al.  Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase , 1995, Journal of virology.

[27]  S. Gulnik,et al.  Kinetic characterization and cross-resistance patterns of HIV-1 protease mutants selected under drug pressure. , 1995, Biochemistry.

[28]  M. Kuroda,et al.  Impaired infectivity of HIV-1 after a single point mutation in the POL gene to escape the effect of a protease inhibitor in vitro. , 1995, Virology.

[29]  M. Busch,et al.  Dual human immunodeficiency virus type 1 infection and recombination in a dually exposed transfusion recipient. The Transfusion Safety Study Group , 1995, Journal of virology.

[30]  H. Nitschko,et al.  Resistance of HIV type 1 to proteinase inhibitor Ro 31-8959. , 1995, AIDS research and human retroviruses.

[31]  J. Condra,et al.  In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors , 1995, Nature.

[32]  Jack R. Collins,et al.  Flap opening in HIV-1 protease simulated by ‘activated’ molecular dynamics , 1995, Nature Structural Biology.

[33]  P. Sharp,et al.  Recombination in HIV-1 , 1995, Nature.

[34]  D. Ho,et al.  Selection and analysis of human immunodeficiency virus type 1 variants with increased resistance to ABT-538, a novel protease inhibitor , 1995, Journal of virology.

[35]  S Foundling,et al.  Effect of point mutations on the kinetics and the inhibition of human immunodeficiency virus type 1 protease: relationship to drug resistance. , 1995, Biochemistry.

[36]  J. Coffin,et al.  HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy , 1995, Science.

[37]  A. Perelson,et al.  Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection , 1995, Nature.

[38]  Martin A. Nowak,et al.  Viral dynamics in human immunodeficiency virus type 1 infection , 1995, Nature.

[39]  I B Duncan,et al.  Characterization of human immunodeficiency virus type 1 mutants with decreased sensitivity to proteinase inhibitor Ro 31-8959. , 1995, Virology.

[40]  O. Turriziani,et al.  Identification of an amino acid substitution involved in the reduction of sensitivity of HIV-1 to an inhibitor of viral proteinase. , 1994, Acta virologica.

[41]  Dale J. Kempf,et al.  Influence of Stereochemistry on Activity and Binding Modes for C2 Symmetry-Based Diol Inhibitors of HIV-1 Protease , 1994 .

[42]  P. Darke,et al.  L-735,524: an orally bioavailable human immunodeficiency virus type 1 protease inhibitor. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[43]  D Norbeck,et al.  Characterization of human immunodeficiency virus type 1 variants with increased resistance to a C2-symmetric protease inhibitor , 1994, Journal of virology.

[44]  S. Pettit,et al.  The specificity of the HIV-1 protease , 1993 .

[45]  A. Kaplan,et al.  Partial inhibition of the human immunodeficiency virus type 1 protease results in aberrant virus assembly and the formation of noninfectious particles , 1993, Journal of virology.

[46]  A M Hassell,et al.  A symmetric inhibitor binds HIV-1 protease asymmetrically. , 1993, Biochemistry.

[47]  A M Hassell,et al.  Hydroxyethylene isostere inhibitors of human immunodeficiency virus-1 protease: structure-activity analysis using enzyme kinetics, X-ray crystallography, and infected T-cell assays. , 1992, Biochemistry.

[48]  D. Lambert,et al.  Human immunodeficiency virus type 1 protease inhibitors irreversibly block infectivity of purified virions from chronically infected cells , 1992, Antimicrobial Agents and Chemotherapy.

[49]  Erik De Clercq,et al.  HIV inhibitors targeted at the reverse transcriptase. , 1992 .

[50]  J. Huff,et al.  HIV protease: a novel chemotherapeutic target for AIDS. , 1991, Journal of medicinal chemistry.

[51]  S. Freer,et al.  Design of enzyme inhibitors using iterative protein crystallographic analysis. , 1991, Journal of medicinal chemistry.

[52]  R. Dixon,et al.  Expression of active human immunodeficiency virus type 1 protease by noninfectious chimeric virus particles , 1991, Journal of virology.

[53]  I. Weber,et al.  Studies on the role of the S4 substrate binding site of HIV proteinases , 1991, FEBS letters.

[54]  V. Vogt,et al.  Properties of avian retrovirus particles defective in viral protease , 1990, Journal of virology.

[55]  I B Duncan,et al.  Rational design of peptide-based HIV proteinase inhibitors. , 1990, Science.

[56]  A Wlodawer,et al.  Structure of complex of synthetic HIV-1 protease with a substrate-based inhibitor at 2.3 A resolution. , 1989, Science.

[57]  M. Jaskólski,et al.  Conserved folding in retroviral proteases: crystal structure of a synthetic HIV-1 protease. , 1989, Science.

[58]  J. Sodroski,et al.  Role of capsid precursor processing and myristoylation in morphogenesis and infectivity of human immunodeficiency virus type 1. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[59]  B. Ho,et al.  Role of human immunodeficiency virus type 1-specific protease in core protein maturation and viral infectivity , 1989, Journal of virology.

[60]  B. Dunn,et al.  Effective blocking of HIV‐1 proteinase activity by characteristic inhibitors of aspartic proteinases , 1989, FEBS letters.

[61]  M. Navia,et al.  Three-dimensional structure of aspartyl protease from human immunodeficiency virus HIV-1 , 1989, Nature.

[62]  D. Veber,et al.  HIV-1 protease specificity of peptide cleavage is sufficient for processing of gag and pol polyproteins. , 1988, Biochemical and biophysical research communications.

[63]  E. Lillehoj,et al.  Purification and structural characterization of the putative gag-pol protease of human immunodeficiency virus , 1988, Journal of virology.

[64]  L J Davis,et al.  Active human immunodeficiency virus protease is required for viral infectivity. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[65]  A. Skalka,et al.  Synthetic peptides as substrates and inhibitors of a retroviral protease. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[66]  H. Varmus,et al.  Characterization of ribosomal frameshifting in HIV-1 gag-pol expression , 1988, Nature.

[67]  C. Debouck,et al.  Human immunodeficiency virus protease expressed in Escherichia coli exhibits autoprocessing and specific maturation of the gag precursor. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[68]  E. Reddy,et al.  HTLV-III gag protein is processed in yeast cells by the virus pol-protease. , 1986, Science.

[69]  T. Miyata,et al.  Retroviral protease-like sequence in the yeast transposon Ty 1 , 1985, Nature.

[70]  M. Shibuya,et al.  Murine leukemia virus maturation: protease region required for conversion from "immature" to "mature" core form and for virus infectivity. , 1985, Virology.

[71]  A. Kingsman,et al.  Retroviral protease-like sequence in the yeast transposon Ty 1(reply) , 1985, Nature.

[72]  S. Goff,et al.  A deletion mutation in the 5' part of the pol gene of Moloney murine leukemia virus blocks proteolytic processing of the gag and pol polyproteins , 1985, Journal of virology.

[73]  Katherine Spindler,et al.  Rapid evolution of RNA genomes. , 1982, Science.

[74]  A. Berger,et al.  On the size of the active site in proteases. I. Papain. , 1967, Biochemical and biophysical research communications.

[75]  ntonio,et al.  A SHORT-TERM STUDY OF THE SAFETY, PHARMACOKINETICS, AND EFFICACY OF RITONAVIR, AN INHIBITOR OF HIV-1 PROTEASE , 2000 .

[76]  J. Condra,et al.  In vivo selection of HIV-1 variants with reduced susceptibility to the protease inhibitor L-735,524 and related compounds. , 1996, Advances in experimental medicine and biology.

[77]  M. Andreoni,et al.  Saquinavir/zidovudine combination in patients with advanced HIV infection and no prior antiretroviral therapy: CD4+ lymphocyte/plasma RNA changes, and emergence of HIV strains with reduced phenotypic sensitivity. , 1996, Antiviral research.

[78]  B. Sadler,et al.  In vitro antiviral activity of 141W94 (VX-478) in combination with other antiretroviral agents. , 1996, Antiviral research.

[79]  J. Collins,et al.  Activated dynamics of flap opening in HIV-1 protease. , 1995, Advances in experimental medicine and biology.

[80]  M. Murcko,et al.  Crystal Structure of HIV-1 Protease in Complex with Vx-478, a Potent and Orally Bioavailable Inhibitor of the Enzyme , 1995 .

[81]  A. Wlodawer,et al.  Structure-based inhibitors of HIV-1 protease. , 1993, Annual review of biochemistry.

[82]  E. De Clercq.  HIV inhibitors targeted at the reverse transcriptase. , 1992, AIDS research and human retroviruses.